- Home
- BDTX vs SLS Comparison
BDTX vs SLS Comparison
Compare BDTX & SLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BDTX
- SLS
- Stock Information
- Founded
- BDTX 2014
- SLS 2012
- Country
- BDTX United States
- SLS United States
- Employees
- BDTX N/A
- SLS N/A
- Industry
- BDTX Biotechnology: Biological Products (No Diagnostic Substances)
- SLS Biotechnology: Pharmaceutical Preparations
- Sector
- BDTX Health Care
- SLS Health Care
- Exchange
- BDTX Nasdaq
- SLS Nasdaq
- Market Cap
- BDTX 181.4M
- SLS 165.6M
- IPO Year
- BDTX 2020
- SLS N/A
- Fundamental
- Price
- BDTX $2.76
- SLS $1.63
- Analyst Decision
- BDTX Strong Buy
- SLS Strong Buy
- Analyst Count
- BDTX 5
- SLS 1
- Target Price
- BDTX $13.40
- SLS $7.00
- AVG Volume (30 Days)
- BDTX 914.3K
- SLS 1.7M
- Earning Date
- BDTX 08-07-2025
- SLS 08-12-2025
- Dividend Yield
- BDTX N/A
- SLS N/A
- EPS Growth
- BDTX N/A
- SLS N/A
- EPS
- BDTX 0.25
- SLS N/A
- Revenue
- BDTX $70,000,000.00
- SLS N/A
- Revenue This Year
- BDTX N/A
- SLS N/A
- Revenue Next Year
- BDTX N/A
- SLS N/A
- P/E Ratio
- BDTX $11.03
- SLS N/A
- Revenue Growth
- BDTX N/A
- SLS N/A
- 52 Week Low
- BDTX $1.20
- SLS $0.77
- 52 Week High
- BDTX $6.75
- SLS $2.27
- Technical
- Relative Strength Index (RSI)
- BDTX 52.31
- SLS 45.73
- Support Level
- BDTX $2.22
- SLS $1.50
- Resistance Level
- BDTX $2.84
- SLS $1.66
- Average True Range (ATR)
- BDTX 0.20
- SLS 0.10
- MACD
- BDTX -0.01
- SLS -0.00
- Stochastic Oscillator
- BDTX 72.00
- SLS 43.33
About BDTX Black Diamond Therapeutics Inc.
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under the pipeline are BDTX-4933 and BDTX-1535.
About SLS SELLAS Life Sciences Group Inc.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.